Pharmhouse Corp (PHSE) - Net Assets
Based on the latest financial reports, Pharmhouse Corp (PHSE) has net assets worth $19.21 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.33 Million) and total liabilities ($2.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PHSE asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $19.21 Million |
| % of Total Assets | 90.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | -115.77% |
| 10-Year Change | -10048648.55% |
| Growth Volatility | 18761.76 |
Pharmhouse Corp - Net Assets Trend (1996–2024)
This chart illustrates how Pharmhouse Corp's net assets have evolved over time, based on quarterly financial data. Also explore Pharmhouse Corp balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Pharmhouse Corp (1996–2024)
The table below shows the annual net assets of Pharmhouse Corp from 1996 to 2024. For live valuation and market cap data, see Pharmhouse Corp (PHSE) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.00 Million | -324.39% |
| 2023-12-31 | $-236.54K | -106.72% |
| 2022-12-31 | $3.52 Million | -45.60% |
| 2021-12-31 | $6.47 Million | +1.74% |
| 2020-12-31 | $6.36 Million | +32431.48% |
| 2019-12-31 | $-19.68K | -7.62% |
| 2018-12-31 | $-18.29K | -4.93% |
| 2017-12-31 | $-17.43K | -407.62% |
| 2015-12-31 | $5.67K | +56616.72% |
| 2014-12-31 | $9.99 | -100.00% |
| 1998-12-31 | $570.54K | -83.87% |
| 1997-12-31 | $3.54 Million | -44.83% |
| 1996-12-31 | $6.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharmhouse Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2353.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $851.64K | % |
| Other Components | $11.36 Million | % |
| Total Equity | $-1.00 Million | 100.00% |
Pharmhouse Corp Competitors by Market Cap
The table below lists competitors of Pharmhouse Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Spirax-Sarco Engineering PLC
LSE:SPX
|
$63.82 Million |
|
Datavan International
TWO:3521
|
$63.83 Million |
|
Novotek AB
ST:NTEK-B
|
$63.85 Million |
|
Southland Holdings Inc.
NYSE MKT:SLND
|
$63.85 Million |
|
OPAL Fuels Inc
NASDAQ:OPAL
|
$63.79 Million |
|
SNC Former Public Company Limited
BK:SNC
|
$63.75 Million |
|
Eversendai Corporation Bhd
KLSE:5205
|
$63.74 Million |
|
PT Pelayaran Tamarin Samudra Tbk
JK:TAMU
|
$63.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharmhouse Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -236,538 to -1,003,849, a change of -767,311.
- Net loss of 777,071 reduced equity.
- Other comprehensive income increased equity by 103,410.
- Other factors decreased equity by 93,650.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-777.07K | -77.41% |
| Other Comprehensive Income | $103.41K | +10.3% |
| Other Changes | $-93.65K | -9.33% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Pharmhouse Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $0.00 | $0.07 | x |
| 2014-12-31 | $0.00 | $0.07 | x |
| 2015-12-31 | $0.00 | $0.07 | x |
| 2017-12-31 | $0.00 | $0.07 | x |
| 2018-12-31 | $0.00 | $0.07 | x |
| 2019-12-31 | $0.00 | $0.07 | x |
| 2020-12-31 | $0.07 | $0.07 | x |
| 2021-12-31 | $0.07 | $0.07 | x |
| 2022-12-31 | $0.04 | $0.07 | x |
| 2023-12-31 | $0.00 | $0.07 | x |
| 2024-12-31 | $0.00 | $0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharmhouse Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-68.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -13.83% | -7.20% | 1.04x | 1.85x | $-1.53 Million |
| 1997 | -85.72% | -21.58% | 1.62x | 2.45x | $-3.39 Million |
| 1998 | -637.14% | -43.02% | 2.45x | 6.04x | $-3.69 Million |
| 2014 | 14.91% | 6.65% | 0.40x | 5.57x | $0.49 |
| 2015 | -0.08% | -0.03% | 0.36x | 7.19x | $-571.04 |
| 2017 | 0.00% | -30.94% | 0.27x | 0.00x | $-373.00 |
| 2018 | 0.00% | -39.57% | 0.11x | 0.00x | $969.90 |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $574.30 |
| 2020 | -85.15% | 0.00% | 0.00x | 1.04x | $-6.06 Million |
| 2021 | -5.32% | 0.00% | 0.00x | 1.02x | $-992.13K |
| 2022 | -83.81% | 0.00% | 0.00x | 1.11x | $-3.30 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.31 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-676.69K |
Industry Comparison
This section compares Pharmhouse Corp's net assets metrics with peer companies in the Lodging industry.
Industry Context
- Industry: Lodging
- Average net assets among peers: $541,750,809
- Average return on equity (ROE) among peers: 2.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharmhouse Corp (PHSE) | $19.21 Million | -13.83% | 0.11x | $63.79 Million |
| Atour Lifestyle Holdings Limited American Depositary Shares (ATAT) | $1.19 Billion | 8.41% | 3.01x | $4.31 Billion |
| Choice Hotels International Inc (CHH) | $-113.80 Million | 0.00% | 0.00x | $4.63 Billion |
| Civeo Corp (CVEO) | $237.00 Million | -7.20% | 0.71x | $359.39 Million |
| GreenTree Hospitality Group Ltd (GHG) | $2.13 Billion | 4.16% | 1.22x | $82.78 Million |
| Hyatt Hotels Corporation (H) | $640.00 Million | 32.97% | 0.30x | $6.85 Billion |
| Hilton Worldwide Holdings Inc (HLT) | $-3.69 Billion | 0.00% | 0.00x | $72.90 Billion |
| Huazhu Group Ltd (HTHT) | $902.26 Million | 4.72% | 0.75x | $15.67 Billion |
| The Intergroup Corporation (INTG) | $4.60 Million | -32.61% | 7.22x | $59.65 Million |
| Marriott International Inc (MAR) | $3.57 Billion | 7.75% | 1.32x | $83.82 Billion |
About Pharmhouse Corp
Pride Holdings Group operates as a LGBTQ-focused entertainment, hospitality, and lifestyle company in the United States. It engages in the bar, pub, tavern, restaurant, hotels, nightclubs, and live adult entertainment industry businesses. The company was formerly known as Parliament House Enterprises, Inc. and changed its name to Pride Holdings Group in July 2025. Pride Holdings Group is based in… Read more